20 results about "Leptospira" patented technology

The invention discloses a spirochete-like multiplex nucleic acid detection kit and a matched artificial chromosome engineering bacterium quality control product, and belongs to the field of molecular biology. The kit comprises a leptospira specific primer probe group, a hot-regressive spirospira specific primer probe group, a borrelia burgdorferi specific primer probe group and other PCR reaction system components, and can realize high-specificity, high-sensitivity and high-accuracy quantitative detection of target genes of the leptospira, the hot-regressive spirospira and the borrelia burgdorferi. The standard requirements of fluorescent PCR and digital PCR multi-gradient standard curve establishment, nucleic acid extraction kit performance verification and clinical diagnosis are met. According to the quality control product, target gene consistency sequences of leptospira, retro-hot spirospira and borrelia burgdorferi are integrated into an escherichia coli artificial chromosome through a homologous recombination technology, the extraction characteristic of a cell structure simulation sample is reserved, the copy number is calibrated through digital PCR, and the quality control product has nuclease degradation resistance.

The present invention is directed to providing a canine with protective immunity against Leptospira serovar Grippoty-phosa with a vaccine that comprises a non-Grippotyphosa Leptospira serovar.

The application provides a primer probe set, a kit and application for quantitatively detecting murine infectious agents, and belongs to the technical field of genetic engineering.The six-reagent quantitative detection kit (fluorescent PCR method) for tsutsugamushi oriental body, fever with thrombocytopenia syndrome virus, prrillonella, hantavirus, leptospira, and rickettsia mooseri can detect the six pathogenic targets of tsutsugamushi oriental body, fever with thrombocytopenia syndrome virus, prrillonella, hantavirus, leptospira, and rickettsia mooseri in one reaction, and accurately quantitatively analyzes each pathogenic target.Through single-tube reaction, parallel detection and quantification of the six pathogenic targets are realized, the time consumed due to misjudgment of the targets is reduced, the consumption of consumables and the occupation of instrument space caused by multi-tube reaction are reduced.The quantitative results reflect the pathogenic load, and provide efficient detection and application support for rapid identification and quantitative monitoring of samples of murine origin or samples of the environment related to mouse activities.

The invention provides a vaccine prepared from Gleisseria parasuis SmpA protein and related tandem protein thereof and application, and belongs to the technical field of veterinary biological products. The invention relates to a vaccine prepared from a Gleisseria parasuis SmpA protein, and further relates to recombinant proteins SmpA-OppA1 and OppA1-SmpA which are expressed in a tandem manner, and recombinant proteins SmpA-PalA and PalA-SmpA which are expressed in a tandem manner, namely SmpA and OppA1 recombinant proteins SmpA-OppA1 and OppA1-SmpA. Experiment results show that the SmpA protein, the SmpA-OppA1 and OppA1-SmpA, and the SmpA-PalA and PalA-SmpA all have the obvious advantage and characteristic of strong immune protection efficacy, and after the SmpA protein, the SmpA-OppA1 and OppA1-SmpA as well as the SmpA-PalA and PalA-SmpA are mixed with an adjuvant, the prepared swine Graisseria subunit vaccine has the advantages of simple process and good safety, can effectively resist the infection of Graisseria parasuis, and lays a foundation for industrial production of the swine Graisseria subunit vaccine.

The present invention belongs to the field of biotechnology, and specifically relates to single-chain antibodies against pathogenic Leptospira, preparation methods and applications. Phage display technology is used to construct an immune library by immunizing rabbit spleens with Leptospira. After five rounds of solid-phase panning with decreasing antigen concentrations, ELISA identification and sequencing analysis, specific single-chain antibodies are screened. The host bacteria switching expression process is optimized to achieve efficient preparation of soluble single-chain antibodies. The antibodies have high sensitivity in sandwich ELISA detection and do not cross-react with common pathogens. In animal model treatment, the cocktail combination significantly improves the survival rate of infected golden hamsters and reduces the leptospira load in the kidneys, providing an innovative solution for the development of diagnostic reagents, antigen epitope identification and targeted treatment of leptospirosis.

The present invention provides methods and compositions for determining the presence and / or amount of pathogenic Leptospira in a test sample. In particular, substantially purified oligonucleotide primers and probes are described that can be used for qualitatively and quantitatively detecting pathogenic Leptospira nucleic acid in a test sample by amplification methods. The present invention also provides primers and probes for generating and detecting control nucleic acid sequences that provide a convenient method for assessing internal quality control of the Leptospira assay.

The present invention relates to a combination of a first vaccine comprising a non-replicating immunogen of porcine erysipelothrix sp. And a non-replicating immunogen of porcine parvovirus and a second vaccine comprising a non-replicating immunogen of leptospira sp. And the first vaccine and the second vaccine are jointly injected into corium layers of a first injection part and a second injection part of the pig at different points to prophylactically treat the pig so as to resist swine erysipelothrix erysipelas infection, porcine parvovirus infection and leptospirosis infection.

The present invention discloses a strain of Lactobacillus mucosus from guinea pigs JL20 and its application, belonging to the field of biomedicine. Lactobacillus mucosus from guinea pigs JL20 was deposited in the General Microbiology Center of the China National Committee for the Collection of Microorganisms on July 19, 2023, with the deposit number CGMCC No. 27949. Lactobacillus mucosus from guinea pigs JL20 can be used as an adjuvant in leptospira vaccines, and has the effects of enhancing vaccine potency, improving antibody quality, and enhancing the reactivity of antigen-presenting cells. It is also convenient to administer, significantly reduces the vaccine dosage, reduces production costs, is safe and has no side effects, and reduces the production of inflammatory side effects caused by vaccine immunization, and has very important application value.

The invention provides a mutant of phenylalanine tRNA (transfer ribonucleic acid) alpha subunit synthetase mPheS of rhinotrichum gloeosporioides, which has T257A and A304G double-site mutation relative to a wild type amino acid sequence, the invention further provides a coding gene of the mutant, and the gene of the mutant is applied to microbial gene knockout. An efficient gene traceless knockout strategy of the rhinotrichum-like is established, and efficient gene traceless knockout of the rhinotrichum-like can be achieved.

The invention relates to the technical field of biological detection, and discloses a composition for detecting hemorrhagic fever related pathogens, a kit and application. The composition comprises detection primers and probes for various serotypes of dengue fever viruses, burkholderia pseudomallei, leptospira, plasmodium noiri and other pathogens causing hemorrhagic fever diseases, the pathogens can be detected at the same time through a multiplex PCR technology, the detection speed is high, the efficiency is high, and the detection time is short. The method has the advantages of high accuracy and sensitivity.

The invention provides a virulence modifying (VM) protein-based composition or vaccine for administration to a subject, comprising a recombinant VM protein antigen or a recombinant viral vector expressing a VM protein antigen and a pharmaceutically or veterinarily acceptable adjuvant. The invention further provides a method for vaccinating a subject susceptible to leptospirosis infection or eliciting an immune response in the subject against leptospirosis comprising administering the vaccine to the subject. The invention also provides a method for diagnosing leptospirosis in a subject by quantifying the presence of a secreted, leptospiral VM protein antigen that mediates disease pathogenesis in the subject.

The invention provides a virulence modifying (VM) protein-based composition or vaccine for administration to a subject, comprising a recombinant VM protein antigen or a recombinant viral vector expressing a VM protein antigen and a pharmaceutically or veterinarily acceptable adjuvant. The invention further provides a method for vaccinating a subject susceptible to leptospirosis infection or eliciting an immune response in the subject against leptospirosis comprising administering the vaccine to the subject. The invention also provides a method for diagnosing leptospirosis in a subject by quantifying the presence of a secreted, leptospiral VM protein antigen that mediates disease pathogenesis in the subject.

The application discloses a fluorescent probe primer, a kit and application of the fluorescent probe primer for five bodies of pigs, wherein the five bodies of pigs include porcine rickettsia, porcine chlamydia, mycoplasma hyopneumoniae, toxoplasma and leptospira. The application selects the conserved sequences of porcine rickettsia ORF5 genes, porcine chlamydia glgp genes, mycoplasma hyopneumoniae P95 genes, toxoplasma B1 genes and leptospira CLPS genes to design probe primers, the kit can simultaneously analyze a large number of samples, and whether the samples contain mycoplasma hyopneumoniae, chlamydia, rickettsia, toxoplasma and leptospira can be identified at one time, and the kit has the characteristics of simplicity, rapidness, good stability, high sensitivity and strong specificity.

The application relates to the technical field of molecular biology detection, and specifically discloses a Leptospira rapid detection kit based on CRISPR-Cas12a, which comprises an amplification module reagent, a CRISPR detection module reagent, a sample pretreatment module reagent and a quality control module reagent; the double-target strategy can realize the following advantages through complementary identification information: on one hand, a pathogenic gene directly indicates a potential pathogenic strain, and the direct indication can enhance the directionality of disease correlation; on the other hand, a 16S variable region provides lineage or close strain identification, and can distinguish environmental / non-pathogenic background noise from a real pathogenic threat. The design reduces the risk of false positive or false negative caused by a single target in molecular recognition, improves the reliability and availability of detection results in clinical interpretation and epidemiological explanation, and provides more definite information support for subsequent diagnosis and treatment or prevention and control decision-making after rapid screening.

The invention relates to the technical field of polypeptide vaccines, in particular to a BPSL1050-based rhinotrichum-like polypeptide and application thereof. The invention discloses a BPSL1050-based rhinotrichum-like polypeptide antigen, and the amino acid sequence of the BPSL1050-based rhinotrichum-like polypeptide antigen is as shown in SEQ ID NO. 6 or as shown in SEQ ID NO. 7. The polypeptide antigen has a B cell epitope and T cell epitope overlapping region with strong immunogenicity, and can effectively excite experimental animals to generate high-titer and specific antibodies. According to the technical scheme, the technical problem that in the prior art, a polypeptide antigen which can be used for developing an effective polypeptide vaccine aiming at rhinotrichum gloeosporioides and is simple in structure is lacked can be solved, and the polypeptide antigen gives consideration to immunogenicity and structural simplicity, has good safety, stability and broad-spectrum applicability, has wide clinical transformation and application prospects, and has wide application prospects. The method is especially suitable for prevention and control of infectious diseases which severely threaten public health safety and is similar to nasal carbuncle.

Provided are Leptospiral virulence modifying (VM) protein epitopes, and their use as vaccines and for generating therapeutic antibodies.

The invention provides compositions and methods for using Leptospiral virulence modifying (VM) proteins or fragments or fusions thereof, as vaccines and as therapeutic agents for the treatment of cancer.

The present invention is directed to providing a canine with protective immunity against Leptospira serovar Icterohaemorrhagiae with a vaccine that comprises non-Icterohaemorrhagiae Leptospira serovar.

The application discloses a canine leptospira, icterohaemorrhagia leptospira and canine coronavirus triple inactivated vaccine. The application is prepared by adding adjuvant after inactivation of the canine leptospira, icterohaemorrhagia leptospira and canine coronavirus epidemic strain separated in China. The application relates to a pathogen separation culture, identification, inactivation method, production process, vaccine storage and immunization method. The canine triple inactivated vaccine is used for preventing canine leptospira disease, icterohaemorrhagia leptospira disease and canine coronavirus disease, and high antibodies can be generated after immunization of the canine, and the high antibodies have a good protective effect on virulent attack. The leptospira is a zoonosis, the canine is a companion animal of human, and the pet canine is in close contact with human, so the triple inactivated vaccine has good social benefits and important public health significance.

The invention relates to the technical field of microbiological detection, and discloses a primer probe group and a kit for detecting pathogenic leptospira and application of the primer probe group and the kit. The primer probe group comprises a primary PCR (Polymerase Chain Reaction) primer group and a secondary PCR primer probe group, the first-time PCR primer group comprises a primer 16SrRNA-F1 as shown in SEQ ID NO: 1, a primer 16SrRNA-R1 as shown in SEQ ID NO: 2, a primer 23SrRNA-F1 as shown in SEQ ID NO: 3 and a primer 23SrRNA-R1 as shown in SEQ ID NO: 4, and the first-time PCR primer group comprises a primer 16SrRNA-F1 as shown in SEQ ID NO: 2 and a primer 23SrRNA-R1 as shown in SEQ ID NO: 3; the primary PCR primer probe group comprises a primer 16SrRNA-F2 as shown in SEQ ID NO: 1, a primer 16SrRNA-R2 as shown in SEQ ID NO: 2, a primer 23SrRNA-F2 as shown in SEQ ID NO: 8 and a primer 23SrRNA-R2 as shown in SEQ ID NO: 10, and the secondary PCR primer probe group comprises a primer 16SrRNA-F2 as shown in SEQ ID NO: 3, a primer 16SrRNA-R2 as shown in SEQ ID NO: 4 and a primer 23SrRNA-R2 as shown in SEQ ID NO: 5. By adopting the primer probe group and the kit, 15 common serotype pathogenic hook bodies can be effectively detected, and the primer probe group and the kit are high in detection sensitivity and specificity, short in detection time and low in detection cost.